Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 32Active not recruiting 24Completed 17Terminated 5Not yet recruiting 4Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Genitourinary 1

Conditions

Breast Neoplasms 3Prostatic Neoplasms 1Hypogonadism 1Carcinoma, Ductal 1

Interventions

Specimen Handling 76Cisplatin 64Drug Therapy 63Carboplatin 63Bevacizumab 63Magnetic Resonance Spectroscopy 59Radiotherapy 57Gemcitabine 54Cyclophosphamide 54pembrolizumab 52Oxaliplatin 49Capecitabine 49toripalimab 44Paclitaxel 40tislelizumab 39Standard of Care 39fludarabine 36Injections 34Fluorouracil 34Biopsy 34venetoclax 33Blood Specimen Collection 31Immune Checkpoint Inhibitors 30anlotinib 28Nivolumab 28Surgical Procedures, Operative 27Irinotecan 27Docetaxel 27Leucovorin 26Dexamethasone 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Tamoxifen × 1 year × Clear all
NCT07287098 2026-05-22

preEMBER

Eli Lilly and Company

Phase 2 Not yet recruiting
600 enrolled
Breast

Breast Neoplasms

NCT07535905 2026-04-17

REVIVE

University Health Network, Toronto

Phase 2 Not yet recruiting
96 enrolled
Genitourinary

Hypogonadism, Prostatic Neoplasms

NCT07499999 2026-03-30

BabyTEARS

Dana-Farber Cancer Institute

Phase 2 Not yet recruiting
140 enrolled
Breast

Breast Neoplasms, Carcinoma, Ductal

NCT07101159 2025-08-03

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

Fujian Cancer Hospital

Phase 2 Not yet recruiting
200 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡